Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren's syndrome after Rituximab therapy.
Chronic acquired demyelinating polyneuropathies may be refractory to conventional therapy including corticosteroids, plasma exchange, and intravenous immunoglobulin (Ig) or require long-term immunotherapy to maintain remission. Use of alternative approaches such as Rituximab, an anti-CD20 antibody, in the treatment of demyelinating polyneuropathy, unrelated to IgM gammopathy and myelin-associated glycoprotein antibodies, has been the subject of only a few case reports. We report the case of a 79-year-old woman with a distal acquired demyelinating polyneuropathy in the context of Sjögren's syndrome, IgG paraproteinemia, and occult lymphoma who has had an excellent and durable response to Rituximab therapy.
Botez
Stephan A
SA
Department of Neurology, University of Rochester, Rochester, NY, USA.
Herrmann
David N
DN
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D004576:Electromyography / Q000379:methods; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008223:Lymphoma / Q000150:complications / Q000628:therapy; D009431:Neural Conduction / Q000187:drug effects; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000150:complications / Q000628:therapy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab